These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
473 related articles for article (PubMed ID: 11522640)
1. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640 [TBL] [Abstract][Full Text] [Related]
2. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. Palucka AK; Dhodapkar MV; Paczesny S; Burkeholder S; Wittkowski KM; Steinman RM; Fay J; Banchereau J J Immunother; 2003; 26(5):432-9. PubMed ID: 12973032 [TBL] [Abstract][Full Text] [Related]
3. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
5. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986 [TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Fay JW; Palucka AK; Paczesny S; Dhodapkar M; Johnston DA; Burkeholder S; Ueno H; Banchereau J Cancer Immunol Immunother; 2006 Oct; 55(10):1209-18. PubMed ID: 16331519 [TBL] [Abstract][Full Text] [Related]
7. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. Banchereau J; Ueno H; Dhodapkar M; Connolly J; Finholt JP; Klechevsky E; Blanck JP; Johnston DA; Palucka AK; Fay J J Immunother; 2005; 28(5):505-16. PubMed ID: 16113607 [TBL] [Abstract][Full Text] [Related]
8. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568 [TBL] [Abstract][Full Text] [Related]
9. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Banchereau J; Fay J; Pascual V; Palucka AK Novartis Found Symp; 2003; 252():226-35; discussion 235-8, 257-67. PubMed ID: 14609222 [TBL] [Abstract][Full Text] [Related]
11. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790 [TBL] [Abstract][Full Text] [Related]
13. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411 [TBL] [Abstract][Full Text] [Related]
14. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732 [TBL] [Abstract][Full Text] [Related]
15. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058 [TBL] [Abstract][Full Text] [Related]
16. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017 [TBL] [Abstract][Full Text] [Related]
17. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657 [TBL] [Abstract][Full Text] [Related]
20. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]